– USA, CA – Pfenex Inc. (NYSE: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology to improve protein therapies for unmet patient needs, today announced the appointment of Lorianne Masuoka, MD to its Board of Directors, effective immediately. Dr. Masuoka was also appointed to serve as a member of the compensation committee.
“We are pleased to welcome Dr. Masuoka to the Pfenex Board of Directors. Her appointment further aligns the Board with the Company’s strategy to build a new R&D capability. We believe Dr. Masuoka’s extensive experience successfully expanding the development pipelines of several biotech companies makes her a valuable counselor to the Pfenex executive team as the Company further leverages the Pfēnex Expression Technology platform to build out its development pipeline,” said Jason Grenfell-Gardner, Chairman of Pfenex.
About Dr Lorianne Masuoka
Dr. Masuoka has more than 20 years of experience building and expanding high-value pipelines in the biopharmaceutical industry that have resulted in drug approvals and strategic alliances. She is a board-certified neurologist that has successfully created and overseen high performing teams to lead the clinical development of new medicines, with a focus in neurology, CNS, and pain. Dr. Masuoka served as chief medical officer of InVivo Therapeutics, Cubist Pharmaceuticals (now Merck), and Nektar Therapeutics where, as a member of executive management, she oversaw and managed teams in the areas of clinical research, drug safety, biostatistics and data management, regulatory affairs, reimbursement and clinical operations. Previously, she held various roles of increasing responsibility at FivePrime Therapeutics and Chiron.
“I am honored to join the Pfenex Board and have an opportunity to work with my fellow board members and the management team at this ever-important point in the Company’s history,” stated Dr. Masuoka. “I look forward to lending my broad R&D and operational experience, including prioritizing programs and establishing research pipelines, as I support the Pfenex team in their mission to develop exciting new opportunities that further leverage the Pfēnex Expression Technology platform and drive long-term shareholder value.”
Dr. Masuoka received her medical degree from the University of California, Davis, where she also completed her residency in neurology. She completed her epilepsy fellowship at Yale University and is board certified by the American Board of Psychiatry and Neurology.
About Pfenex Inc.
Pfenex is a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology to develop and improve protein therapies for unmet patient needs. Using the patented Pfēnex Expression Technology platform, the Company has created an advanced pipeline of potential therapeutic equivalents, novel biologics, vaccine and vaccine components, and biosimilars. The Company’s lead product candidate is PF708, a therapeutic equivalent candidate to Forteo for the treatment of osteoporosis. In addition, in collaboration with Jazz Pharmaceuticals Ireland Limited the Company is developing hematologic oncology products including PF743, a recombinant crisantaspase, and PF745, a recombinant crisantaspase with half-life extension. Both PF743 and PF745 are being developed for the treatment of Acute Lymphoblastic Leukemia. We also use our Pfēnex Expression Technology platform to produce CRM197, a diphtheria toxoid carrier protein used in prophylactic and therapeutic vaccine candidates under development by third parties.
For more information: https://www.pfenex.com
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.